PubMed
Dihexa, a small molecule that promotes new synapse formation, demonstrates cognitive enhancement
McCoy et al., 2013
Neurological & CognitiveResearch OnlyB
Dihexa
PNB-0408
Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a potent hepatocyte growth factor (HGF) receptor agonist originally developed at Washington State University. Preclinical studies in rodents show it enhances synaptic connectivity and spatial memory retention — with reported potency millions of times greater than BDNF. No published human clinical trials exist. Research only; use with caution.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 7
- Research grade
- B
- Experience
- 56
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About Dihexa
Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a potent hepatocyte growth factor (HGF) receptor agonist originally developed at Washington State University. Preclinical studies in rodents show it enhances synaptic connectivity and spatial memory retention — with reported potency millions of times greater than BDNF. No published human clinical trials exist. Research only; use with caution.
- Category
- Neurological & Cognitive
- Regulatory status
- Research Only
- Also known as
- PNB-0408
- Self-reports
- 19
Community
What 19 users report
19 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Cognition
143
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
3
2+ mg
140
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 84% said they felt similar to their last entry, 16% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 141 days · Based on 19 repeat reporters
Research
Cited research (5)
Source
PubMed
Angiotensin IV analog dihexa facilitates learning and memory
Benoist et al., 2011
ClinicalTrials.gov
Dihexa studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies
Ho et al., 2018
PubMed
The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases
Wright et al., 2015
Tools
Explore more
Explore
More ways to learn about Dihexa from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about Dihexa?
This page summarizes 19 anonymized self-reports from PeptIQ users who track Dihexa, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Dihexa?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Dihexa?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Dihexa safe to use?
This wiki does not assess safety or recommend use. Dihexa is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Dihexa?
This wiki summarizes observational community reports and linked citations for Dihexa. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for Dihexa for study-level context — not medical advice.
What is the legal status of Dihexa?
Dihexa is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of Dihexa?
Safety data quality for Dihexa varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on Dihexa?
This page links 5 indexed sources for Dihexa. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.